News archive - AddBIO

New CTO at AddBIO

2014-09-15T07:34:38+02:00

As from September 1st, Anders Petersson has joined AddBIO as CTO. Anders is one of the founders of Osstell AB and comes from a position as CTO of that company. Anders holds a Master of Science in Physics, and previous experience includes various positions at Nobel Biocare AB.

Having Anders as part of the organisation is in line with the Companys' strategy to build a strong team to take the AddBIO Products to market, and we believe that this recruitment is an important step.

Anders Petersson, CTO AddBIO

First ever machine to add bone-strengthening drugs to implants

2014-06-25T11:09:59+02:00

Addbio is introducing the Zolidiser, the first ever machine to add bone-strengthening drugs to implants on an industrial scale. The Zolidiser is purpose-made, a one of its kind machine, developed to enable commercialization of the Addbio product Zolidd.

"Addition of bone-strengthening drugs to implants will change the industry" states Philip Procter, orthopaedic industry expert. The Zolidiser was developed in close collaboration with Addbio partners Pharmaceutical Business Consultants Ltd (PBC) in Shannon, Ireland, and Devex Mekatronik in Linköping and has a capacity of up to 60 000 coated screw implants a year. Manufacturing and final development steps before launch are to be set up at PBC who have both extensive industry experience and appropriate clean room facilities.

AddBIO CTO is moving on

2014-06-24T11:08:54+02:00

AddBIO has reached an important milestone with the completion of the first ever machine to add bone-strengthening drugs to implants on an industrial scale. Dr. Trine Vikinge has been instrumental in the development together with an international team of renowned consultants. They have taken the Zolidd technology from the university laboratory through to being an industry compatible and regulatory feasible product.

Dr Vikinge has now decided to leave AddBIO to take on new challenges elsewhere and therefore people with different skills will now be engaged in the further development of AddBIO.

Clinical results – Zolidd improves function of external fixation pins

2013-05-06T09:32:00+02:00

A randomized clinical trial shows that Zolidd improves the function of orthopedic external fixation pins.

External fixation with threaded pins is an easy and practical method for (minimally invasive) fracture fixation. It is mainly used for temporary fixation, because of problems with loosening and pin-tract infection, especially in spongeous (porous) bone. This problem can be largely overcome by the use of a hydroxyapatite (HA) coating. HA enables bone formation directly on the pin surface, which reduces loosening, but creates new problems such as difficult and painful removal. In the present study, implants with bisphosphonate were compared to implants coated with HA, as well as plain stainless steel implants.

“The study shows that local bisphosphonate improves the fixation in spongeous bone to the same degree that HA does. However, removal was as easy as with uncoated pins”, says Professor Per Aspenberg, Linköping University Hospital, co-author of the study and co-founder of AddBIO.

The study is published in Acta Orthopaedica http://informahealthcare.com/doi/abs/10.3109/17453674.2013.797315

Peter Selley appointed Chairman of the board

2013-03-05T10:03:00+01:00

AddBIO has appointed Peter Selley, previously CEO of Astra Tech AB, as Chairman of the Board.

Peter Selley has an extensive experience from the medical device and dental implants industry. During10 years as the CEO of Astra Tech, Peter Selley developed the business into one of the globally market leading dental implant companies. Peter Selley then led the internal divestment team when Astra Tech was acquired by Dentsply in 2011.

Regulatory expert Keith Summerhayes to join AddBIO

2013-03-04T09:04:00+01:00

Senior Clinical Research Professional Keith Summerhayes will take the place of Emma Gundersen who is going on maternal leave. Keith has 30 years of experience working with product development in medical technology, and has a broad understanding particularly in regulatory and quality management issues. Keith has worked with major US & European ‘blue chip’ Pharmaceutical, Contract Research and Orthopaedic Medical Device Corporations and has got significant experience in start-up medical device companies.

We welcome Keith to his new position!

Better understanding of local bisphosphonate

2013-02-15T09:18:14+01:00

Giving a bisphosphonate drug locally around a dental implant, instead of systemically, totally omitted the problem with osteonecrosis of the jaw, even when provoked by complementary medication.

The research group of Addbio co-founder professor Aspenberg continues to increase the understanding of how local administration of bisphosphonate drugs works. In a recent paper (Abtahi 2012) they have contributed significantly to the understanding of how a locally delivered such drug behaves differently with respect to side-effects. (Abstract on PubMed) In short, laboratory rats had teeth extracted and replaced by dental implants, metal screws. All rats given a systemic dose of bisphosphonate and an immunosuppressive drug (dexamethasone) experienced osteonecrosis, and the implants came loose. On the contrary, the group given the dexamethasone, and then the bisphosphonate locally around the screw rather than systemically, experienced that none of the implants loosened. In these rats, the implant stability was significantly improved, even when compared to control groups.

The article again demonstrates how a local dose of a bisphosphonate significantly improves the biomechanical performance and functional outcome of a dental implant.

Ulf Sewerin Addbio CEO

2012-12-10T10:50:30+01:00

AddBIO AB has recruited Ulf Sewerin as CEO. Most recently, Ulf Sewerin has worked as a consultant in the dental implant industry, and prior to this he was Area Director for the Asia Pacific region and Area Manager for UK and Ireland at Biomet 3i.

New AddBIO board members

2012-12-10T10:49:55+01:00

AddBIO has appointed Gunilla Lundmark, Dr. Andy Carter, and Maria Fors to the company’s board of directors.

Successful share issue

2012-12-10T10:49:20+01:00

The funds will be used to advance the companies relations with dental implants companies, and enable collaborations in order to finalize the product.